Caricamento quotazioni...
Previsioni
Non sono disponibili dati degli analisti per questa azienda.
Discussioni nella community
- Aktiensplit: Eckert & Ziegler Strahlen (DE0005659700)
Wir haben heute den Split für DE0005659700 ausgeführt (der war bereits Anfang August). Das ist der erste Split den Tresor One handelt und dient als Test vor Apple und Tesla am Sonntag/Montag,…
Sumit IV in Schnack 2 11
Notizie Vai al feed delle notizie
Eckert und Ziegler needs positive Q3 impulses to break downtrend
The stock of Eckert und Ziegler has moved up from its yearly low but remains in a medium- to long-term downtrend. Analysts at NuWays expect an acceleration of earnings growth ahead of the Q3 results on November 12, driven by higher profitability in the Isotope Products division as well as rising sales of lutetium‑177 and licence income. Technically, the stock must overcome short-term hurdles around €13, just under €14 and the 200-day line at roughly €14.40; on the downside it needs to hold €12.50/€12.60, otherwise a retest of the yearly low at €12 looms. » Altro su finanzen.net
Eckert & Ziegler signs supply agreement for terbium-161 with TerThera
Eckert & Ziegler has signed an agreement with Dutch provider TerThera for the supply of the radionuclide terbium-161 for radioligand therapies. Terbium-161 is to be added to Eckert & Ziegler’s portfolio in Brazil to shorten the supply chain and improve regional access to theranostic solutions. The news helped the stock move off its year low, but a sustainable bottoming has not yet been achieved. » Altro su finanzen.net
Eckert und Ziegler confirms 2026 targets, stock remains under pressure
Eckert und Ziegler has once again confirmed its targets for 2026: revenue around €320 million and adjusted EBIT of about €80 million. Investors are responding cautiously, the stock is generally moving downward and the chart technicals signal further pressure. Adjusted for currency effects and the licensing business, reported revenue and earnings show growth, but real growth is significantly more moderate. » Altro su finanzen.net
Eckert und Ziegler face further share losses due to geopolitical risks and missed targets
Geopolitical tensions in the Gulf are raising energy costs and making transport and logistics more expensive for Eckert und Ziegler, which could dampen demand. Adjusted EBIT after H1 was €33.3m, well below the annual target of around €80m, and revenue has reached €149.3m of the roughly planned €320m. Given this development, strong Q3 figures are unlikely; the stock has been in a downtrend since July and could technically fall from support at around €12.20 to just under €11, though single‑digit prices still appear distant. » Altro su finanzen.net
Eckert & Ziegler disappoints with half-year figures and breaks chart support
Eckert & Ziegler reported only modest revenue growth in the first half of 2026 to €149.3m, with adjusted EBIT down 6% to €33.3m. Targets for 2026 were confirmed, but reaching an adjusted EBIT of around €80m could become riskier after delays in gallium-generator deliveries caused by a cyber attack and a weak Isotope Products segment. The share fell through repeatedly tested levels and broke support at €13.30, putting a further decline toward about €12.40 at risk. Long term, the potential remains intact thanks to large actinium-225 capacities and expansion opportunities in China. » Altro su finanzen.net
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 79,6 Mln | 5,69% |
| Utile lordo | 0 | 100,00% |
| Utile netto | 13,1 Mln | 54,90% |
| EBITDA | 19,3 Mln | 0,47% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 959,92 Mln € |
Numero di azioni | 62,58 Mln |
Massimo/minimo a 52 settimane | 16,84 € - 11,91 € |
Rendimento da dividendo | 1,43% |
Dividendi TTM | 0,22 € |
Beta | 1,47 |
Rapporto P/E | 17,63 |
Rapporto PEG | 0,49 |
Rapporto P/B | 3,58 |
Rapporto P/S | 3,03 |
Profilo aziendale
Eckert & Ziegler Strahlen- und Medizintechnik AG, tramite le sue controllate, produce e vende componenti per la tecnologia isotopica destinati ad applicazioni mediche, scientifiche e industriali in tutto il mondo. L'azienda opera in due segmenti, Medical e Isotope Products. Il segmento Medical offre piccoli impianti radioattivi per il trattamento del cancro alla prostata, sotto forma di semi, e applicazioni oculari basate su rutenio-106 o iodio-125 per il trattamento del melanoma uveale. Questo segmento fornisce inoltre radiofarmaci, apparecchiature di laboratorio, celle calde e servizi per i radiofarmaci, nonché applicatori oculari e impianti per la prostata. Il segmento Isotope Products produce e vende sorgenti di radiazioni per l'imaging, la tecnologia di misura, l'analisi dei materiali, il controllo di qualità e il monitoraggio ambientale. Questo segmento offre anche sorgenti di calibrazione per i sistemi di imaging medicale, nonché prodotti per la sicurezza nazionale e per la misurazione radiometrica del livello. La società è stata fondata nel 1992 e ha sede a Berlino, in Germania.
| Nome | Eckert & Ziegler |
| CEO | Harald Hasselmann |
| Sede centrale | Berlin,
be Germania |
| Sito web | |
| Settore | Sanità |
| Industria | Tecnologia sanitaria |
| Quotazione in borsa | 26/05/1999 |
| Dipendenti | 1116 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
XETRA | EUZ.DE |
Frankfurt | EUZ.F |
Düsseldorf | EUZ.DU |
Hamburg | EUZ.HM |
Milan | 1EUZ.MI |
London | 0NZY.L |
SIX | EUZ.SW |
München | EUZ.MU |